g is being developed under a $140mn contract with the US. Department of Defense's Medical Countermeasure Systems Bio0efense Therapeutics (MCS-BDTX) Joint Product Management Office. The FDA ascribed a fast track status to this drug as it is targeting an unmet medical need since there are no therapies available for acute Ebola